Clinical Trial

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Study acronym: Breakfree-SSc
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Not Yet Recruiting 2026-08-04
critical Recruitment opened 2026-05-16
Trial Details
NCT Number NCT07335562
Lead Sponsor Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Collaborators: Celgene Corporation
Conditions Systemic Sclerosis
Enrollment 92 participants
Start Date 2026-08-29
Primary Completion 2028-11-14 (estimated)
Study Completion 2030-11-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03